|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Schering-Plough_(2009)
|
|
gptkbp:alsoKnownAs
|
gptkb:MSD_(outside_US_and_Canada)
|
|
gptkbp:CEO
|
gptkb:Robert_M._Davis
|
|
gptkbp:division
|
gptkb:biotechnology
animal health
pharmaceuticals
vaccines
|
|
gptkbp:founded
|
1891
|
|
gptkbp:founder
|
gptkb:George_Merck
|
|
gptkbp:headquarters_location
|
gptkb:Kenilworth,_New_Jersey,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Merck & Co. (US)
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:listedOn
|
gptkb:Fortune_500
|
|
gptkbp:member
|
gptkb:Dow_Jones_Industrial_Average_(past)
gptkb:Pharmaceutical_Research_and_Manufacturers_of_America
|
|
gptkbp:notableCase
|
gptkb:Vioxx_litigation
|
|
gptkbp:notablePerson
|
gptkb:Maurice_Hilleman
gptkb:Max_Tishler
gptkb:Emil_von_Behring
gptkb:Satoshi_Ōmura
gptkb:Paul_Janssen
gptkb:Thomas_Huckle_Weller
gptkb:William_C._Campbell
gptkb:John_Sheehan
gptkb:Karl_Folkers
|
|
gptkbp:notableProduct
|
gptkb:Gardasil
gptkb:Isentress
gptkb:Januvia
gptkb:Keytruda
gptkb:Propecia
gptkb:Singulair
gptkb:Zetia
gptkb:Vioxx
|
|
gptkbp:notablePublication
|
gptkb:Merck_Manual
|
|
gptkbp:nowPartOf
|
gptkb:Merck_Group_(Germany)
|
|
gptkbp:numberOfEmployees
|
~69,000 (2023)
|
|
gptkbp:parentCompany
|
independent (public company)
|
|
gptkbp:R&D_spending
|
$13.5 billion (2022)
|
|
gptkbp:revenue
|
$59.3 billion (2022)
|
|
gptkbp:S&P500Component
|
yes
|
|
gptkbp:separates
|
gptkb:Merck_Group_(1917)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:NYSE
|
|
gptkbp:stockSymbol
|
gptkb:MRK
|
|
gptkbp:subsidiary
|
gptkb:Merck_Research_Laboratories
gptkb:MSD_Animal_Health
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
https://www.merck.com/
|
|
gptkbp:bfsParent
|
gptkb:Merck
|
|
gptkbp:bfsLayer
|
5
|